CRISPR Therapeutics (CRSP)
(Delayed Data from NSDQ)
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.92 USD
+0.35 (0.61%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $58.50 +0.58 (1.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.
Vertex Terminates COO Ian Smith on Code of Conduct Violation
by Zacks Equity Research
Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.
Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag
by Zacks Equity Research
FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.
Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint
by Zacks Equity Research
Vertex (VRTX) reports positive phase II data of its pipeline candidate VX-150 in patients with pain caused by small fiber neuropathy.
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $38.33, marking a -1.01% move from the previous day.
CRISPR Therapeutics AG (CRSP) Stock Moves -0.55%: What You Should Know
by Zacks Equity Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $36.17, moving -0.55% from the previous trading session.
Spectrum (SPPI) Earnings and Sales Beat Estimates in Q3
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in the third quarter and also beats on revenues. The company is on track to file a BLA for Rolontis by year end.
Is CRISPR THERAPTC (CRSP) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CRSP) Outperforming Other Medical Stocks This Year?
CRISPR THERAPTC (CRSP) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CRISPR THERAPTC (CRSP) delivered earnings and revenue surprises of -44.59% and -83.91%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Cronos (CRON) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Cronos (CRON) reports third-quarter results.
CRISPR THERAPTC (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
CRISPR THERAPTC (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo (PRGO) focuses on growth strategy for Consumer Healthcare Americas segment. The company plans to divest its loss-making Rx segment.
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) partnered programs - Kyprolis and Promacta - using its Captisol formulation technology are expected to drive milestone and royalty payments in third-quarter 2018.
Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.
Endo (ENDP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on the Xiaflex performance and pipeline updates when Endo (ENDP) reports third-quarter results.
Is a Beat in Store for Humana (HUM) Stock in Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) Q3 is likely to gain from solid segmental performances and higher enrollment.
ImmunoGen (IMGN) Beats on Earnings in Q3, Lowers Guidance
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss in Q3. However, it misses estimates for revenues. Shares down.
What's in the Cards for Nektar (NKTR) This Earnings Season?
by Zacks Equity Research
Nektar Therapeutics (NKTR) will report third-quarter results on Nov 7. Investors are expected to focus on pipeline progress.
5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings
by Zacks Equity Research
There are still a number of drug/biotech companies poised to surpass third-quarter estimates.
VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports narrower-than-expected loss in the third quarter. Sales increase year over year.
Geron's (GERN) Q3 Earnings Beat, Revenues Miss, Shares Down
by Zacks Equity Research
Geron (GERN) beats earnings estimates in the third quarter but misses on revenues. Operating expenses decrease year over year.
Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus
by Zacks Equity Research
Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.
Match Group (MTCH) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Match Group (MTCH) boasts of a robust product portfolio comprising Tinder, Match.com, Meetic, PlentyOfFish and OkCupid.
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) third-quarter conference call, investor focus will be on the company's progress with its proprietary genome editing platform based on CRISPR technology.
What's in Store for Verastem (VSTM) This Earnings Season?
by Zacks Equity Research
On Verastem's (VSTM) third-quarter conference call, investor focus will be on the company's launch and reimbursement plans for its newly approved leukemia drug Copiktra.